Stefan Knapp
Stefan Knapp
Verified email at
Cited by
Cited by
Selective inhibition of BET bromodomains
P Filippakopoulos, J Qi, S Picaud, Y Shen, WB Smith, O Fedorov, ...
Nature 468 (7327), 1067-1073, 2010
Histone recognition and large-scale structural analysis of the human bromodomain family
P Filippakopoulos, S Picaud, M Mangos, T Keates, JP Lambert, ...
Cell 149 (1), 214-231, 2012
Targeting bromodomains: epigenetic readers of lysine acetylation
P Filippakopoulos, S Knapp
Nature reviews Drug discovery 13 (5), 337-356, 2014
Protein production and purification
Architecture et Fonction des Macromolécules Biologiques Vincentelli Renaud 4 ...
Nature methods 5 (2), 135-146, 2008
The promise and peril of chemical probes
CH Arrowsmith, JE Audia, C Austin, J Baell, J Bennett, J Blagg, C Bountra, ...
Nature chemical biology 11 (8), 536-541, 2015
Critical residues for structure and catalysis in short-chain dehydrogenases/reductases
C Filling, KD Berndt, J Benach, S Knapp, T Prozorovski, E Nordling, ...
Journal of Biological Chemistry 277 (28), 25677-25684, 2002
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs
KL Kavanagh, K Guo, JE Dunford, X Wu, S Knapp, FH Ebetino, ...
Proceedings of the National Academy of Sciences 103 (20), 7829-7834, 2006
Bromodomains as therapeutic targets
S Muller, P Filippakopoulos, S Knapp
Expert reviews in molecular medicine 13, e29, 2011
Large-scale structural analysis of the classical human protein tyrosine phosphatome
AJ Barr, E Ugochukwu, WH Lee, ONF King, P Filippakopoulos, I Alfano, ...
Cell 136 (2), 352-363, 2009
Linear motif atlas for phosphorylation-dependent signaling
ML Miller, LJ Jensen, F Diella, C Jørgensen, M Tinti, L Li, M Hsiung, ...
Science signaling 1 (35), ra2-ra2, 2008
Copper is required for oncogenic BRAF signalling and tumorigenesis
DC Brady, MS Crowe, ML Turski, GA Hobbs, X Yao, A Chaikuad, S Knapp, ...
Nature 509 (7501), 492-496, 2014
Small-molecule inhibition of BRDT for male contraception
MM Matzuk, MR McKeown, P Filippakopoulos, Q Li, L Ma, JE Agno, ...
Cell 150 (4), 673-684, 2012
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
S Picaud, C Wells, I Felletar, D Brotherton, S Martin, P Savitsky, ...
Proceedings of the National Academy of Sciences 110 (49), 19754-19759, 2013
Trends in kinase drug discovery: targets, indications and inhibitor design
MM Attwood, D Fabbro, AV Sokolov, S Knapp, HB Schiöth
Nature Reviews Drug Discovery 20 (11), 839-861, 2021
The bromodomain interaction module
P Filippakopoulos, S Knapp
FEBS letters 586 (17), 2692-2704, 2012
Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
KVM Huber, E Salah, B Radic, M Gridling, JM Elkins, A Stukalov, ...
Nature 508 (7495), 222-227, 2014
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers
L Brault, C Gasser, F Bracher, K Huber, S Knapp, J Schwaller
haematologica 95 (6), 1004, 2010
Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?
Z Zhao, H Wu, L Wang, Y Liu, S Knapp, Q Liu, NS Gray
ACS chemical biology 9 (6), 1230-1241, 2014
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases
O Fedorov, B Marsden, V Pogacic, P Rellos, S Müller, AN Bullock, ...
Proceedings of the National Academy of Sciences 104 (51), 20523-20528, 2007
Crystal structure of the tetrameric Mad1–Mad2 core complex: implications of a ‘safety belt’binding mechanism for the spindle checkpoint
L Sironi, M Mapelli, S Knapp, A De Antoni, KT Jeang, A Musacchio
The EMBO journal, 2002
The system can't perform the operation now. Try again later.
Articles 1–20